Published ,
Reading 2 mins.
The Medicines Agency has suspended the marketing and use of injectable products supposed to destroy fat to fight against obesity. These products do not have marketing authorization and adverse effects should be taken seriously.
Drugs supposed to fight against obesity on sale on the internet are singled out by the National Agency for the Safety of Medicines and Health Products (ANSM). They don’t haveis the subject of no application for marketing authorization (MA)”, can we read in the communicated Wednesday, December 15. Consequently, the Agency decided to suspend their marketing and use.
Potentially dangerous products that have not proven the slightest effectiveness
“We inform people or professionals who wish to order them on the internet that these products are potentially dangerous for health andno clinical studies have been conducted to demonstrate their effectiveness. informs the document.
These products, intended for use by injection and sold as being able to eliminate localized fat or fat cells, are composed of phosphatidylcholine and/or sodium deoxycholate. Several practices using this technique of “adipocyte lysis” have already been banned in France since 2012, recalls the Ministry of Health.
In case of side effects, make an appointment with the doctor
The ANSM reminds us that we cannot say that these are drugs since they have not obtained marketing authorization. Also the health risks can be considerable: “extensive hematomas, skin infections, non-infectious skin necrosis that may require surgical interventions. These complications have for some been followed by disabling sequelae (chronic pain, reduced mobility, etc.) and aesthetics”.
If you have used these products and you notice an adverse effect, the ANSM recommends make an appointment with your doctor as soon as possible treating. If you are in possession of these products and have not used them yet, bring them back to your pharmacist who can dispose of them in an appropriate container.
“If the act of lipolysis was performed by a health professional, the user or his attending physician must inform the authorities via the portal www.signalement-sante.gouv.fr. If the act of lipolysis was not carried out by a healthcare professional, the user or his attending physician must inform his regional health agency (ARS).”